{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:37Z","timestamp":1790982997276,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,25]]},"DOI":"10.7759\/cureus.113368","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:18:53Z","timestamp":1785014333000},"source":"Crossref","is-referenced-by-count":1,"title":["When Weight Loss Turns Dangerous: A Case Report of Tirzepatide-Induced Ketoacidosis in a Non-diabetic Woman"],"prefix":"10.7759","author":[{"given":"Humaid","family":"Sadiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor M","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O","family":"Alao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiagarajan","family":"Jaiganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): A double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-55. 10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type\u00a02 diabetes: The SURPASS clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type\u00a02 diabetes: The SURPASS clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard FS","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MB, et al.. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020, 5:e140532. 10.1172\/jci.insight.140532","journal-title":"JCI Insight"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004357","article-title":"Tirzepatide-induced ketoacidosis in non-diabetic patients","volume":"11","author":"Iqbal PM","year":"2024","unstructured":"Iqbal PM, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. Eur J Case Rep Intern Med. 2024, 11:004357. 10.12890\/2024_004357","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.946133","article-title":"Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: Is starvation the culprit?","volume":"25","author":"Bitar Z","year":"2024","unstructured":"Bitar Z, Abdelraouf HM, Maig RA, Maadarani O, Bitar ZZ, Dashti H. Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: Is starvation the culprit?. Am J Case Rep. 2024, 25:e946133. 10.12659\/AJCR.946133","journal-title":"Am J Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000517305","article-title":"Starvation ketosis and the kidney","volume":"52","author":"Palmer BF","year":"2021","unstructured":"Palmer BF, Clegg DJ. Starvation ketosis and the kidney. Am J Nephrol. 2021, 52:467-78. 10.1159\/000517305","journal-title":"Am J Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-025-01749-x","article-title":"GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: A brief review","volume":"49","author":"Sood N","year":"2025","unstructured":"Sood N, Buddhavarapu V, Garg R. GLP-1 receptor agonists causing euglycemic ketoacidosis in patients without diabetes: A brief review. Int J Obes (Lond). 2025, 49:977-9. 10.1038\/s41366-025-01749-x","journal-title":"Int J Obes (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.107028","article-title":"Severe euglycemic ketoacidosis secondary to tirzepatide use for weight loss","volume":"18","author":"Hassan A","year":"2026","unstructured":"Hassan A. Severe euglycemic ketoacidosis secondary to tirzepatide use for weight loss. Cureus. 2026, 18:e107028. 10.7759\/cureus.107028","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.97410","article-title":"An online prescription for hospitalisation: Euglycaemic ketoacidosis caused by an online tirzepatide prescription","volume":"17","author":"Sathambihai T","year":"2025","unstructured":"Sathambihai T, Mathur K, Siddavaram S. An online prescription for hospitalisation: Euglycaemic ketoacidosis caused by an online tirzepatide prescription. Cureus. 2025, 17:e97410. 10.7759\/cureus.97410","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/514224-when-weight-loss-turns-dangerous-a-case-report-of-tirzepatide-induced-ketoacidosis-in-a-non-diabetic-woman","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:18:53Z","timestamp":1785014333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/514224-when-weight-loss-turns-dangerous-a-case-report-of-tirzepatide-induced-ketoacidosis-in-a-non-diabetic-woman"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.113368","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}